- DKK23.99bn
- DKK36.02bn
- DKK22.00bn
- 71
- 76
- 11
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 8.69 | ||
| Price to Sales | 1.09 | ||
| EV to EBITDA | 6.32 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.76% | ||
| Return on Equity | 13.36% | ||
| Operating Margin | 14.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 17,672 | 16,299 | 18,246 | 19,912 | 22,004 | n/a | n/a | 5.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +2.52 | -32.19 | +20.89 | +15.8 | +57.71 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Directors
- Lars Rasmussen NEC (62)
- Deborah Dunsire PRE (59)
- Lene Skole-Soerensen VCH (62)
- Anders Goetzsche CFO (54)
- Lars Bang EVP (59)
- Johan Luthman EVP (63)
- Jacob Tolstrup EVP (49)
- Lars Holmqvist DRC (62)
- Rikke Kruse Andreasen DRC (51)
- Henrik Sindal Jensen DRC (52)
- Ludovic Tranholm Otterbein DRC (48)
- Henrik Andersen IND (54)
- Santiago Arroyo IND (61)
- Jeffrey Berkowitz IND (56)
- Jeremy Levin IND (68)
- Dorothea Wenzel IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 14th, 1950
- Public Since
- January 1st, 1999
- No. of Shareholders
- 50,000
- No. of Employees
- 5,707
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange - Copenhagen- Shares in Issue
- 991,227,477
- Address
- Ottiliavej 9, VALBY, 2500
- Web
- https://www.lundbeck.com/
- Phone
- +45 null36301311
- Contact
- Palle Olesen
- Auditors
- PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELS
Upcoming Events for HLUN B
Similar to HLUN B
Alk-Abello A/S
OMX Nordic Exchange - Copenhagen
Bavarian Nordic A/S
OMX Nordic Exchange - Copenhagen
H Lundbeck A/S
OMX Nordic Exchange - Copenhagen
Novo Nordisk A/S
OMX Nordic Exchange - Copenhagen
StenoCare A/S
OMX Nordic Exchange - Copenhagen
FAQ
As of Today at 21:07 UTC, shares in H Lundbeck A/S are trading at DKK28.56. This share price information is delayed by 15 minutes.
Shares in H Lundbeck A/S last closed at DKK28.56 and the price had moved by -13.45% over the past 365 days. In terms of relative price strength the H Lundbeck A/S share price has underperformed the FTSE Global All Cap Index by -14.98% over the past year.
There is no consensus recommendation for this security.
Find out moreThe H Lundbeck A/S dividend yield is 3.33% based on the trailing twelve month period.
Last year, H Lundbeck A/S paid a total dividend of DKK0.95, and it currently has a trailing dividend yield of 3.33%. We do not have any data on when H Lundbeck A/S is to next pay dividends.
We do not have data on when H Lundbeck A/S is to next pay dividends. The historic dividend yield on H Lundbeck A/S shares is currently 3.33%.
To buy shares in H Lundbeck A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of DKK28.56, shares in H Lundbeck A/S had a market capitalisation of DKK23.99bn.
Here are the trading details for H Lundbeck A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: HLUN B
Based on an overall assessment of its quality, value and momentum H Lundbeck A/S is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like H Lundbeck A/S. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -38.32%.
As of the last closing price of DKK28.56, shares in H Lundbeck A/S were trading -32.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The H Lundbeck A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at DKK28.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
H Lundbeck A/S' management team is headed by:
- Lars Rasmussen - NEC
- Deborah Dunsire - PRE
- Lene Skole-Soerensen - VCH
- Anders Goetzsche - CFO
- Lars Bang - EVP
- Johan Luthman - EVP
- Jacob Tolstrup - EVP
- Lars Holmqvist - DRC
- Rikke Kruse Andreasen - DRC
- Henrik Sindal Jensen - DRC
- Ludovic Tranholm Otterbein - DRC
- Henrik Andersen - IND
- Santiago Arroyo - IND
- Jeffrey Berkowitz - IND
- Jeremy Levin - IND
- Dorothea Wenzel - IND